Starling Oncology, Inc. (STLNW) shareholders
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
4M
Shares held, 13F filers
Institutional holders
12
1 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
16 buys · 11 sales
Net sold $122.18K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Chernett Jorey | 10,115,944 | 10.20% | 13G (passive) amendment | Mar 13, 2026 |
| M33 Growth I GP LLC Joint filing with M33 Growth I LP (9.79%) | 9,290,838 | 9.79% | 13D (active) amendment | Sep 4, 2025 |
| M33 Growth I LP Joint filing with M33 Growth I GP LLC (5.46%) | 6,802,656 | 5.46% | 13D (active) amendment | Nov 18, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of STLNW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| LMR Partners LLP | 1,624,856 | – | $66.29K | – | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 1,250,000 | – | $51.00K | – | 0.00% |
| Wolverine Asset Management LLC | 418,214 | – | $17.06K | +232,777 | 0.00% |
| Davidson Kempner Capital Management LP | 318,710 | – | $13.00K | – | 0.00% |
| Toronto Dominion Bank | 187,474 | – | $7.69K | −200 | 0.00% |
| Oasis Management Co Ltd. | 100,000 | – | $543.00K | – | 0.03% |
| Man Group plc | 88,824 | – | $2.75K | – | 0.00% |
| Healthcare Of Ontario Pension Plan Trust Fund | 87,500 | – | $2.75K | – | 0.00% |
| Alpine Global Management, LLC | 25,024 | – | $1.02K | – | 0.00% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 25,000 | – | $1.02K | – | 0.00% |
| UBS Group AG | 17,115 | – | $702 | New | 0.00% |
| Clear Street Group Inc. | 6,028 | – | $246 | −200 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 12 | 4M | 1 / 1 | 2 / 0 | 0M | 0M |
| Q1 2026 | 11 | 4M | 0 / 3 | 0 / 0 | 0M | 0M |
| Q4 2025 | 11 | 4M | 0 / 0 | 3 / 1 | 0M | 0M |
| Q3 2025 | 12 | 4M | 3 / 1 | 0 / 1 | 0M | 0M |
| Q2 2025 | 11 | 4M | 1 / 2 | 1 / 1 | 0M | 0M |
| Q1 2025 | 11 | 4M | 0 / 1 | 3 / 3 | 0M | 0M |
| Q4 2024 | 14 | 4M | 1 / 1 | 6 / 2 | 2M | 1M |
| Q3 2024 | 15 | 3M | 0 / 0 | 5 / 3 | 0M | 2M |
| Q2 2024 | 18 | 4M | 3 / 6 | 1 / 0 | 0M | 0M |
| Q1 2024 | 15 | 4M | 0 / 1 | 3 / 1 | 0M | 0M |
| Q4 2023 | 16 | 5M | 4 / 5 | 2 / 2 | 0M | 0M |
| Q3 2023 | 14 | 4M | 2 / 4 | 2 / 2 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Yale Podnos | Chief Medical Officer | 277,501 | Jul 16, 2026 |
| Robert Ross Carter | Chief Financial Officer | 649,975 | May 22, 2026 |
| Daniel Virnich | Chief Executive Officer | 2,337,166 | May 22, 2026 |
| Kristin England | Chief Administrative Officer | 153,780 | Apr 23, 2026 |
| Jeffrey Langsam | Chief Clinical Officer | 127,650 | Apr 23, 2026 |
| Jeremy Castle | Chief Operating Officer | 247,031 | May 22, 2025 |
| Brad Hively | Director | 411,976 | Aug 24, 2026 |
| Anne McGeorge | Director | 332,535 | Jul 29, 2026 |
| Mohit Kaushal | Director | 205,716 | Jul 29, 2026 |
| Mark Stolper | Director | 56,957 | Jul 29, 2026 |
| Kimberly Jo Tzoumakas | Director | 46,301 | Jul 29, 2026 |
| Karen Marie Johnson | Director | 319,410 | Jul 29, 2026 |
| Mark L. Pacala | Director | 511,852 | Jul 29, 2026 |
| Gabriel Ling | Director | 296,502 | Dec 1, 2025 |
| Toi M, Llc | Director | 7,944,207 | Nov 20, 2025 |
| Growth I. L.P. M33 | Director | 16,420,701 | Nov 20, 2025 |
| Growth I. GP LLC M33 | Director | 8,523,281 | Nov 20, 2025 |
| Richard A. Barasch | Director | 4,571,022 | Aug 14, 2025 |
| Jorey Chernett | 10% owner | 10,660,858 | Aug 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brad Hively Director | Aug 21, 2026 | Sale(10b5-1 plan) | −298,853 | $6.51 | $1.95M | 411,976 |
| Jorey Chernett 10% owner | Aug 14, 2026 | Buy | +12,000 | $6.54 | $78.48K | 10,660,858 |
| Brad Hively Director | Jul 27, 2026 | Award | +27,108 | – | – | 710,829 |
| Mark L. Pacala Director | Jul 27, 2026 | Award | +30,120 | – | – | 286,881 |
| Karen Marie Johnson Director | Jul 27, 2026 | Award | +31,124 | – | – | 319,410 |
| Kimberly Jo Tzoumakas Director | Jul 27, 2026 | Award | +29,116 | – | – | 46,301 |
| Mark Stolper Director | Jul 27, 2026 | Award | +31,124 | – | – | 56,957 |
| Mohit Kaushal Director | Jul 27, 2026 | Award | +33,133 | – | – | 205,716 |
| Anne McGeorge Director | Jul 27, 2026 | Award | +41,165 | – | – | 332,535 |
| Jorey Chernett 10% owner | Jul 21, 2026 | Buy | +18,000 | $5.27 | $94.86K | 10,648,858 |
| Yale Podnos Chief Medical Officer | Jul 14, 2026 | Option exercise | +17,974 | $1.87 | $33.61K | 277,501 |
| Yale Podnos Chief Medical Officer | Jul 14, 2026 | Sale(10b5-1 plan) | −17,974 | $6.43 | $115.57K | 259,527 |
| Yale Podnos Chief Medical Officer | Jul 14, 2026 | Sale(10b5-1 plan) | −5,478 | $6.35 | $34.79K | 259,527 |
| Yale Podnos Chief Medical Officer | Jul 14, 2026 | Option exercise | +5,478 | $2.00 | $10.96K | 265,005 |
| Jorey Chernett 10% owner | Jul 10, 2026 | Buy | +15,000 | $5.85 | $87.75K | 10,630,858 |
| Kimberly Jo Tzoumakas Director | Jul 7, 2026 | Award | +17,185 | – | – | 17,185 |
| Mark Stolper Director | Jul 7, 2026 | Award | +25,833 | – | – | 25,833 |
| Jorey Chernett 10% owner | Jun 23, 2026 | Buy | +18,000 | $5.02 | $90.36K | 10,615,858 |
| Yale Podnos Chief Medical Officer | Jun 8, 2026 | Sale(10b5-1 plan) | −23,451 | $5.38 | $126.17K | 259,527 |
| Jorey Chernett 10% owner | Jun 4, 2026 | Buy | +12,000 | $4.75 | $57.00K | 10,579,858 |
| Robert Ross Carter Chief Financial Officer | May 21, 2026 | Other | −1,604 | $4.47 | $7.17K | 414,801 |
| Daniel Virnich Chief Executive Officer | May 21, 2026 | Other | −23,058 | $4.47 | $103.07K | 2,337,166 |
| Yale Podnos Chief Medical Officer | May 21, 2026 | Other | −1,805 | $4.47 | $8.07K | 282,978 |
| Jorey Chernett 10% owner | May 20, 2026 | Buy | +33,500 | $4.07 | $136.35K | 10,567,858 |
| Jorey Chernett 10% owner | May 19, 2026 | Buy | +5,000 | $4.05 | $20.25K | 10,534,358 |
| Jorey Chernett 10% owner | May 19, 2026 | Buy | +30,000 | $4.09 | $122.70K | 10,529,358 |
| Mohit Kaushal Director | Apr 16, 2026 | Sale(10b5-1 plan) | −38,433 | $3.50 | $134.52K | 172,583 |
| Mohit Kaushal Director | Apr 14, 2026 | Sale(10b5-1 plan) | −57,286 | $3.50 | $200.50K | 211,016 |
| Jorey Chernett 10% owner | Apr 9, 2026 | Buy | +20,000 | $3.10 | $62.00K | 10,499,358 |
| Daniel Virnich Chief Executive Officer | Mar 27, 2026 | Other | −98,534 | $3.07 | $302.50K | 2,360,224 |
| Daniel Virnich Chief Executive Officer | Mar 27, 2026 | Award | −670,608 | – | – | 2,458,758 |
| Yale Podnos Chief Medical Officer | Mar 27, 2026 | Other | −16,173 | $3.07 | $49.65K | 284,783 |
| Yale Podnos Chief Medical Officer | Mar 27, 2026 | Award | +66,446 | – | – | 300,956 |
| Robert Ross Carter Chief Financial Officer | Mar 27, 2026 | Other | −20,320 | $3.07 | $62.38K | 416,405 |
| Robert Ross Carter Chief Financial Officer | Mar 27, 2026 | Award | −202,914 | – | – | 436,725 |
| Jeffrey Langsam Chief Clinical Officer | Mar 27, 2026 | Award | +70,270 | – | – | 127,650 |
| Kristin England Chief Administrative Officer | Mar 27, 2026 | Award | +55,743 | – | – | 153,780 |
| Jorey Chernett 10% owner | Mar 27, 2026 | Buy | +27,429 | $2.96 | $81.19K | 10,479,358 |
| Jorey Chernett 10% owner | Mar 26, 2026 | Buy | +50,000 | $3.15 | $157.50K | 10,451,929 |
| Jorey Chernett 10% owner | Mar 24, 2026 | Buy | +125,000 | $3.11 | $388.75K | 10,401,929 |
| Jorey Chernett 10% owner | Mar 20, 2026 | Buy | +25,000 | $3.35 | $83.75K | 10,276,929 |
| Robert Ross Carter Chief Financial Officer | Mar 17, 2026 | Other | −1,314 | $3.59 | $4.72K | 233,811 |
| Yale Podnos Chief Medical Officer | Mar 17, 2026 | Other | −3,420 | $3.59 | $12.28K | 234,510 |
| Daniel Virnich Chief Executive Officer | Mar 17, 2026 | Other | −11,834 | $3.59 | $42.48K | 1,788,150 |
| Jorey Chernett 10% owner | Mar 17, 2026 | Buy | +75,000 | $3.42 | $256.50K | 10,251,929 |
| Jorey Chernett 10% owner | Mar 16, 2026 | Buy | +60,985 | $3.29 | $200.64K | 10,176,929 |
| Jorey Chernett 10% owner | Mar 13, 2026 | Buy | +263,000 | $2.92 | $767.96K | 10,115,944 |
| Robert Ross Carter Chief Financial Officer | Jan 2, 2026 | Other | −244 | $3.67 | $895 | 235,125 |
| Robert Ross Carter Chief Financial Officer | Jan 2, 2026 | Sale | −247 | $3.56 | $879 | 235,122 |
| Brad Hively Director | Dec 15, 2025 | Sale | −13,333 | $3.77 | $50.27K | 683,721 |
| Anne McGeorge Director | Nov 20, 2025 | Award | +40,123 | – | – | 291,370 |
| Anne McGeorge Director | Nov 20, 2025 | Award | +67,901 | – | – | 251,247 |
| Gabriel Ling Director | Nov 20, 2025 | Award | +46,296 | – | – | 296,502 |
| Gabriel Ling Director | Nov 20, 2025 | Award | +37,037 | – | – | 333,539 |
| Brad Hively Director | Nov 20, 2025 | Award | +41,667 | – | – | 664,647 |
| Brad Hively Director | Nov 20, 2025 | Award | +32,407 | – | – | 697,054 |
| Karen Marie Johnson Director | Nov 20, 2025 | Award | +47,840 | – | – | 251,249 |
| Karen Marie Johnson Director | Nov 20, 2025 | Award | +37,037 | – | – | 288,286 |
| Mark L. Pacala Director | Nov 20, 2025 | Award | +46,296 | – | – | 221,267 |
| Mark L. Pacala Director | Nov 20, 2025 | Award | +35,494 | – | – | 256,761 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
4.3
At 0M shares a day
Change since last report
+131.8%
From 0M shares
Short volume, 20 days
52.8%
Of volume reported to FINRA
Shares sold short, last 3 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Starling Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 644 shares on Aug 12, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Bradford Hively Director | Aug 21, 2026 | 298,853 | $1.95M | Aug 21, 2026 | Open Market Purchase |
| Yale Podnos Officer | Jul 14, 2026 | 23,452 | $146.58K | Jul 14, 2026 | Exercise of Stock Options |
| Yale Podnos Officer | Jun 8, 2026 | 23,451 | $114.21K | Jun 8, 2026 | Exercise of Stock Options |
| Mohit Kaushal Director | Apr 14, 2026 | 95,719 | $315.87K | Apr 14, 2026 | Restricted Stock Units |
| Bradford Daniel Hively Director | Dec 15, 2025 | 13,333 | $50.29K | Dec 15, 2025 | Restricted Stock |
| Mark L. Pacala Director | Nov 18, 2025 | 50,000 | $200.00K | Nov 18, 2025 | Restricted Stock |
| Toi M, Llc 10% Stockholder | Jun 5, 2025 | 127,207 | $407.06K | Jun 5, 2025 | SPAC PIPE |
| Growth I. L.P. M33 10% Stockholder | Jun 5, 2025 | 1,122,793 | $3.59M | Jun 5, 2025 | SPAC PIPE |
| Bradford Daniel Hively Director | Jun 3, 2025 | 1,936,537 | $5.56M | Jun 3, 2025 | Exercise of options under a registered plan |
| Bradford Daniel Hively Director | Jun 3, 2025 | 39,600 | $113.65K | Jun 3, 2025 | Restricted stock vesting under a registered plan |
| Growth I. L.P. M33 10% Stockholder | May 20, 2025 | 1,796,468 | $5.50M | May 20, 2025 | SPAC PIPE |
| Toi M, Llc 10% Stockholder | May 20, 2025 | 203,532 | $622.81K | May 20, 2025 | SPAC PIPE |
| Havencrest Healthcare Partners GP, LLC 10% Stockholder | Jan 19, 2024 | 80,000 | $171.20K | Jan 19, 2024 | Public stock issuance |
| Brad Hively Director | Nov 17, 2023 | 25,000 | $56.00K | Nov 17, 2023 | STOCK OPTION EXERCISE |
| Brad Hively Director | Nov 13, 2023 | 47,000 | $118.59K | Nov 13, 2023 | STOCK OPTION EXERCISE |